USFDA19 Aug 2026, 07:40 pm
Strides Pharma's Bengaluru Facility Cleared by USFDA
AI Summary
Strides Pharma Science Ltd announced that its flagship manufacturing facility in Bengaluru has received the Establishment Inspection Report (EIR) from the USFDA, signifying the successful closure of the inspection. The inspection, conducted from May 12-20, 2026, initially resulted in a Form 483 with five observations. Strides submitted a comprehensive response and implemented corrective actions, leading the USFDA to classify the outcome as Voluntary Action Indicated (VAI). This clearance reinforces the company's commitment to quality and its regulatory track record, supporting its supply of pharmaceutical products to global markets.
Key Highlights
- USFDA has issued an EIR for Strides Pharma's Bengaluru facility.
- Inspection concluded with a Voluntary Action Indicated (VAI) classification.
- This successful closure strengthens the company's regulatory standing.
- The facility is crucial for supplying regulated and international markets.
Price Impact
More from STAR